Heart failure drug review reports mixed changes in sleep breathing
Sacubitril/valsartan was linked to improvements in some breathing measures, while the central apnea index rose slightly.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled analysis reported a lower apnea-hypopnea index and higher average oxygen saturation with sacubitril/valsartan, alongside a modest increase in the central apnea index. These mixed physiological findings do not establish better sleep quality or broader health benefits. Missing comparator and follow-up details make the overall clinical meaning difficult to judge.
The abstract omits comparator details, follow-up duration, and measurement units for the reported differences. Its central apnea findings are difficult to reconcile without fuller definitions, so numerical treatment effects are not presented here.
Different breathing measures moved differently
The review used the apnea-hypopnea and central apnea indices as primary outcomes. The first decreased, but the second increased modestly. Oxygen saturation improved on average, making the pattern more complex than a uniform improvement across respiratory measures.
What the abstract cannot settle
The abstract also reports a reduction in patients with central sleep apnea, without enough detail to explain its relationship to the higher central apnea index. Clear definitions and study-level results would be needed to interpret that apparent tension.
The original publication
Impact of sacubitril/valsartan on chronic heart failure patients with sleep-disordered breathing: a systematic review and meta-analysis.
Kuang X, Ye C, Xie Y et al.
Sci Rep · 2025
- PubMed ID
- 40796619
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.